Prurigo nodularis
☆ Liphethong tsa 2022 Stiftung Warentest tse tsoang Jeremane, khotsofalo ea bareki ka ModelDerm e ne e le tlase hanyane ho feta lipuisano tse lefelloang tsa telemedicine.
References
Prurigo nodularis ke boemo ba letlalo bo tšoarellang nako e telele bo khetholloang ke maqhubu a mangata a tiileng le maqhutsu, hangata a fumanoang likarolong tse ka ntle tsa matsoho le maoto. Maqhutsu ana a ka fapana ka 'mala ho tloha ho 'mele ho ea ho o pinki' me a hlohlona haholo. Li ka ama batho ba lilemo life kapa life 'me hangata li amahanngoa le maemo a mang a letlalo a bakang ho hlohlona ho sa foleng, joalo ka dermatitis ea atopic. Mekhoa ea phekolo e kenyelletsa meriana e matla e thibelang ho hlohlona, lithethefatsi tse amang tsamaiso ea 'mele ea ho itšireletsa mafung, le meriana e lebisitseng tsamaiso ea methapo. Ho laola prurigo nodularis hangata ho kenyelletsa phekolo ea nako e telele.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Kalafo hangata e kenyelletsa ho sebelisa litlolo kapa liente tsa steroid sebakeng se amehileng. Maemong a matla kapa a manganga, ho ka hlokahala kalafo e kang kalafo e bobebe kapa meriana e hatellang sesole sa 'mele. Thalidomide le lenalidomide ke likhetho bakeng sa linyeoe tse matla, empa li ka ba le litlamorao tse mpe. Liphekolo tse ncha (opioid receptor antagonists, neurokinin-1 receptor antagonists) li bontša tšepiso ea ho phekola prurigo nodularis ka litla-morao tse fokolang ha li bapisoa le thalidomide kapa lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo ke boemo ba letlalo bo khetholloang ke ho hlohlona ha nako e telele (ho nka libeke tse 6) , liso tsa letlalo tse amanang le ho mengoa, le nalane ea ho ingoaea khafetsa. E kenyelletsa neuroinflammation le fibrosis letlalong.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis ke bothata ba letlalo bo tšoarellang nako e telele bo tšoauoang ke maqhutsu a hlohlona. Ha re tsebe hantle hore na ho bakoa ke eng, empa ho bonahala eka mathata a 'mele oa ho itšireletsa mafung le methapo ea kutlo a na le seabo molemong oa ho hlohlona. Hona joale, ha ho na liphekolo tse amohetsoeng ke US FDA ka ho khetheha bakeng sa prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Kalafo - Lithethefatsi tsa OTC
Ho hlatsoa sebaka se senyehileng ka sesepa ha ho thuse ho hang ebile ho ka mpefatsa boemo. Litlolo tsa OTC steroid li ka thusa ho imolla matšoao, empa hangata li hloka ho sebelisoa libeke tse 'maloa ho ntlafatsa. Ho tsoela pele ho nka li-antihistamine ho boetse ho thusa ho imolla ho hlohlona.
#OTC steroid ointment
#OTC antihistamine
○ Kalafo
#Intralesional triamcinolone injection